David F. Wiemer
Corporate Officer/Principal bei University of Iowa
Profil
David F.
Wiemer is the founder of Terpenoid Therapeutics, Inc. which was founded in 2005.
He held the title of Director from 2012 to 2013.
Currently, he is a Professor at the University of Iowa.
Dr. Wiemer's education history includes an undergraduate degree from Marquette University and a doctorate from the University of Illinois.
Aktive Positionen von David F. Wiemer
| Unternehmen | Position | Beginn |
|---|---|---|
| University of Iowa | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von David F. Wiemer
| Unternehmen | Position | Ende |
|---|---|---|
Terpenoid Therapeutics, Inc.
 Terpenoid Therapeutics, Inc. Medical DistributorsDistribution Services Terpenoid Therapeutics, Inc. operates as a biotechnology company focuses on anti-cancer therapeutics. The firm engages in creating, testing, and developing novel drug candidates using cutting-edge technologies. It is focused on discovering small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indication. The company was founded by Andrew J. Wiemer, Jeffery D. Neighbors, David F. Wiemer and Raymond J. Hohl in September 2005 and is headquartered in Coralville, IA. | Gründer | - |
Ausbildung von David F. Wiemer
| Marquette University | Undergraduate Degree |
| University of Illinois | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Terpenoid Therapeutics, Inc.
Terpenoid Therapeutics, Inc. Medical DistributorsDistribution Services Terpenoid Therapeutics, Inc. operates as a biotechnology company focuses on anti-cancer therapeutics. The firm engages in creating, testing, and developing novel drug candidates using cutting-edge technologies. It is focused on discovering small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indication. The company was founded by Andrew J. Wiemer, Jeffery D. Neighbors, David F. Wiemer and Raymond J. Hohl in September 2005 and is headquartered in Coralville, IA. | Distribution Services |
